Leukaemia (chronic) Cancer
Conditions
Interventions
There are four treatment arms, clinicians may choose to randomise between only arms 1 and 2, 3 and 4, 2 and 4 or to randomise between all treatment arms.
1. Regimen A: Induction thera
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged over 75 years with either Ph positive or Ph negative chronic myeloid leukaemia in chronic phase. Patients over 75 years or patients unwilling to accept alpha-interferon, may be randomised to busulphan or hydroxyurea, but not interferon or no interferon 2. Adequate renal function 3. No severe concurrent hepatic, renal, cardiovascular, organic brain disease or psychiatric illness 4. Patients with established blast cell crisis or extramedullary granulocytic sarcomas are to be excluded 5. Patients with accelerated phase or platelet count below that specified in the protocol are not eligible
Exclusion criteria
Exclusion criteria: Not provided at time of registration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration. | — |
Countries
United Kingdom
Outcome results
None listed